Regis Technologies, Inc. today announced that Tadgh Prendeville has been appointed the new President and CEO of the company. Tadgh will succeed Louis Glunz IV and assume responsibilities on March 21, 2022.
Prendeville comes to Regis from ARx LLC, a family-owned CMDO company where he held the position of President. He is an experienced leader having helped deliver five FDA approvals through innovative pharmaceutical development at ARx LLC. “We are delighted to welcome Tadgh to Regis. His broad experience, proven history of delivering solutions to customers and excellent leadership skills make him an ideal person to lead Regis into the future,” said Jim Sullivan, Chairman of the Board of Directors for Regis Technologies.
Prendeville received his Master of Engineering Science from the University College of Dublin and earned an MBA from the University of Baltimore.
“I am excited to work with the Regis team of expert scientists and accomplished pharmaceutical professionals to continue delivering quality products and expedited pharmaceutical services to our customers. I want to congratulate Louis on a tremendous career at Regis. His commitment to creating a GMP facility and investing in a number of capabilities including Analytical Development, Solid State Chemistry, Potent Compound Synthesis and Chiral Chromatography will leave an enduring legacy,” says Tadgh Prendeville, President and CEO of Regis Technologies.
Glunz will assume the role of Vice-Chairman of the Board of Directors for Regis Technologies and serve as a Strategic Advisor to Prendeville. He said ”The Glunz family remains committed to the Regis mission of expediting drugs to market. Tadgh will continue our values of a family-owned business and I look forward to working closely with him throughout this transition.”